全文获取类型
收费全文 | 167篇 |
免费 | 10篇 |
专业分类
儿科学 | 2篇 |
妇产科学 | 2篇 |
基础医学 | 32篇 |
口腔科学 | 4篇 |
临床医学 | 18篇 |
内科学 | 29篇 |
皮肤病学 | 2篇 |
神经病学 | 22篇 |
特种医学 | 8篇 |
外科学 | 13篇 |
综合类 | 1篇 |
预防医学 | 5篇 |
眼科学 | 1篇 |
药学 | 24篇 |
肿瘤学 | 14篇 |
出版年
2023年 | 1篇 |
2021年 | 9篇 |
2020年 | 1篇 |
2019年 | 3篇 |
2018年 | 4篇 |
2017年 | 1篇 |
2016年 | 2篇 |
2015年 | 6篇 |
2014年 | 13篇 |
2013年 | 11篇 |
2012年 | 17篇 |
2011年 | 24篇 |
2010年 | 13篇 |
2009年 | 8篇 |
2008年 | 14篇 |
2007年 | 12篇 |
2006年 | 6篇 |
2005年 | 10篇 |
2004年 | 6篇 |
2003年 | 5篇 |
2002年 | 8篇 |
1997年 | 1篇 |
1996年 | 1篇 |
1976年 | 1篇 |
排序方式: 共有177条查询结果,搜索用时 15 毫秒
1.
2.
Lusine Nazaryan Eunice G Stefanou Claus Hansen Nadezda Kosyakova Mads Bak Freddie H Sharkey Theodora Mantziou Anastasios D Papanastasiou Voula Velissariou Thomas Liehr Maria Syrrou Niels Tommerup 《European journal of human genetics : EJHG》2014,22(3):338-343
Next-generation mate-pair sequencing (MPS) has revealed that many constitutional complex chromosomal rearrangements (CCRs) are associated with local shattering of chromosomal regions (chromothripsis). Although MPS promises to identify the molecular basis of the abnormal phenotypes associated with many CCRs, none of the reported mate-pair sequenced complex rearrangements have been simultaneously studied with state-of-the art molecular cytogenetic techniques. Here, we studied chromothripsis-associated CCR involving chromosomes 2, 5 and 7, associated with global developmental and psychomotor delay and severe speech disorder. We identified three truncated genes: CDH12, DGKB and FOXP2, confirming the role of FOXP2 in severe speech disorder, and suggestive roles of CDH12 and/or DGKB for the global developmental and psychomotor delay. Our study confirmes the power of MPS for detecting breakpoints and truncated genes at near nucleotide resolution in chromothripsis. However, only by combining MPS data with conventional G-banding and extensive fluorescence in situ hybridizations could we delineate the precise structure of the derivative chromosomes. 相似文献
3.
4.
5.
6.
Non-T cell activation linker (NTAL): a transmembrane adaptor protein involved in immunoreceptor signaling 下载免费PDF全文
Brdicka T Imrich M Angelisová P Brdicková N Horváth O Spicka J Hilgert I Lusková P Dráber P Novák P Engels N Wienands J Simeoni L Osterreicher J Aguado E Malissen M Schraven B Horejsí V 《The Journal of experimental medicine》2002,196(12):1617-1626
A key molecule necessary for activation of T lymphocytes through their antigen-specific T cell receptor (TCR) is the transmembrane adaptor protein LAT (linker for activation of T cells). Upon TCR engagement, LAT becomes rapidly tyrosine phosphorylated and then serves as a scaffold organizing a multicomponent complex that is indispensable for induction of further downstream steps of the signaling cascade. Here we describe the identification and preliminary characterization of a novel transmembrane adaptor protein that is structurally and evolutionarily related to LAT and is expressed in B lymphocytes, natural killer (NK) cells, monocytes, and mast cells but not in resting T lymphocytes. This novel transmembrane adaptor protein, termed NTAL (non-T cell activation linker) is the product of a previously identified WBSCR5 gene of so far unknown function. NTAL becomes rapidly tyrosine-phosphorylated upon cross-linking of the B cell receptor (BCR) or of high-affinity Fcgamma- and Fc epsilon -receptors of myeloid cells and then associates with the cytoplasmic signaling molecules Grb2, Sos1, Gab1, and c-Cbl. NTAL expressed in the LAT-deficient T cell line J.CaM2.5 becomes tyrosine phosphorylated and rescues activation of Erk1/2 and minimal transient elevation of cytoplasmic calcium level upon TCR/CD3 cross-linking. Thus, NTAL appears to be a structural and possibly also functional homologue of LAT in non-T cells. 相似文献
7.
Annkathrin Koch Birte Jeiler Jens Roedig Sjoerd J.L. van Wijk Nadezda Dolgikh Simone Fulda 《Neoplasia (New York, N.Y.)》2021,23(5):539
Burkitt''s lymphoma (BL) is a highly aggressive form of B-cell non-Hodgkin''s lymphoma. The clinical outcome in children with BL has improved over the last years but the prognosis for adults is still poor, highlighting the need for novel treatment strategies. Here, we report that the combinational treatment with the Smac mimetic BV6 and TRAIL triggers necroptosis in BL when caspases are blocked by zVAD.fmk (TBZ treatment). The sensitivity of BL cells to TBZ correlates with MLKL expression. We demonstrate that necroptotic signaling critically depends on MLKL, since siRNA-induced knockdown and CRISPR/Cas9-mediated knockout of MLKL profoundly protect BL cells from TBZ-induced necroptosis. Conversely, MLKL overexpression in cell lines expressing low levels of MLKL leads to necroptosis induction, which can be rescued by pharmacological inhibitors, highlighting the important role of MLKL for necroptosis execution. Importantly, the methylation status analysis of the MLKL promoter reveals a correlation between methylation and MLKL expression. Thus, MLKL is epigenetically regulated in BL and might serve as a prognostic marker for treatment success of necroptosis-based therapies. These findings have crucial implications for the development of new treatment options for BL. 相似文献
8.
Michael M. Kaabak Nadezda N. Babenko Dmitry V. Samsonov Valery A. Sandrikov Alexey A. Maschan Alan K. Zokoev 《Pediatric transplantation》2013,17(2):168-178
Recipient parenchymal lymphatic cells are crucial for direct and indirect pathways of allorecognition. We proposed that alemtuzumab, being infused several weeks pretransplant could eradicate peripheral lymphatic cells and promote donor‐specific tolerance. We present here a single center, retrospective review of 101 consecutive living‐donor kidney transplantations to pediatric patients aged from seven month to 18 yr, performed between September 2006 and April 2010. Immunosupression protocol included two 30 mg doses of alemtuzumab: first given 12–29 d prior to transplantation and second at the time of transplantation. Maintenance immunosupression was based on combination of low dose and wide range CNI and mycophenolate. Patients were followed for 3.8 ± 1.4 yr and protocol biopsies were taken one month, one, and three yr post transplant. The Kaplan–Meier graft and patient survival was 96% and 97% for one yr, 89% and 93% for three yr. Biopsy proven acute rejection developed in 26% patients at one yr and in 35% at two yr, no rejections occurred beyond two yr. We conclude that alemtuzumab pretreatment prior to living related donor kidney transplantation allows to reach satisfactory middle‐term results in pediatric patients with wide range and low CNI concentrations. 相似文献
9.
Anastasia A. Ponomaryova Elena Yu. Rykova Nadezda V. Cherdyntseva Tatiana E. Skvortsova Alexey Yu. Dobrodeev Alexander A. Zav’yalov Leonid O. Bryzgalov Sergey A. Tuzikov Valentin V. Vlassov Pavel P. Laktionov 《Lung cancer (Amsterdam, Netherlands)》2013
To date, aberrant DNA methylation has been shown to be one of the most common and early causes of malignant cell transformation and tumors of different localizations, including lung cancer. Cancer cell-specific methylated DNA has been found in the blood of cancer patients, indicating that cell-free DNA circulating in the blood (cirDNA) is a convenient tumor-associated DNA marker that can be used as a minimally invasive diagnostic test. In the current study, we investigated the methylation status in blood samples of 32 healthy donors and 60 lung cancer patients before and after treatment with neoadjuvant chemotherapy followed by total tumor resection. Using quantitative methylation-specific PCR, we found that the index of methylation (IM), calculated as IM = 100 × [copy number of methylated/(copy number of methylated + unmethylated gene)], for the RASSF1A and RARB2 genes in the cirDNA isolated from blood plasma and cell-surface-bound cirDNA was elevated 2- to 3-fold in lung cancer patients compared with healthy donors. Random forest classification tree model based on these variables combined (RARB2 and RASSF1A IM in both plasma and cell-surface-bound cirDNA) lead to NSCLC patients’ and healthy subjects’ differentiation with 87% sensitivity and 75% specificity. An association of increased IM values with an advanced stage of non-small-cell lung cancer was found for RARB2 but not for RASSF1A. Chemotherapy and total tumor resection resulted in a significant decrease in the IM for RARB2 and RASSF1A, in both cirDNA fractions, comparable to the IM level of healthy subjects. Importantly, a rise in the IM for RARB2 was detected in patients within the follow-up period, which manifested in disease relapse at 9 months, confirmed with instrumental and pathologic methods. Our data indicate that quantitative analysis of the methylation status of the RARB2 and RASSF1A tumor suppressor genes in both cirDNA fractions is a useful tool for lung cancer diagnostics, evaluation of cancer treatment efficiency and post-treatment monitoring. 相似文献